Journal articles: 'Cancérologie digestive'

1

BADER, J. P. "Pourquoi individualiser la cancérologie digestive ?" Cancéro digest, no. 1 (2009): 48. http://dx.doi.org/10.4267/2042/25069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rey, Jean-François. "Cancérologie digestive : L’Importance des UCPO." Acta Endoscopica 34, no. 2 (April 2004): 260–61. http://dx.doi.org/10.1007/bf03009020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Étienne, Jacques, Philippe Ducrotté, Jean-Marc Canard, and Jean-Christophe Létard. "La photothérapie dynamique en cancérologie digestive." Hegel N° 1, no. 1 (2011): 20. http://dx.doi.org/10.4267/2042/38778.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Étienne, Jacques, Philippe Ducrotté, Jean-Marc Canard, and Jean-Christophe Létard. "La photothérapie dynamique en cancérologie digestive." Hegel N° 1, no. 1 (January 1, 2011): 20–25. http://dx.doi.org/10.3917/heg.011.0020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Lledo, G., and P. Artru. "La cancérologie digestive à l’ASCO 2000." Acta Endoscopica 30, S1 (September 2000): 278–82. http://dx.doi.org/10.1007/bf03021871.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mitry, E. "La consultation d’annonce en cancérologie digestive." Côlon & Rectum 1, no. 4 (November 2007): 272–75. http://dx.doi.org/10.1007/s11725-007-0054-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Estable, P. "III.5 Nouveautés en cancérologie digestive." Acta Endoscopica 21, S1 (January 1991): 137–39. http://dx.doi.org/10.1007/bf02970838.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rebischung, C., and M. Laramas. "Les traitements néo-adjuvants en cancérologie digestive." Journal de Chirurgie 144, no. 5 (October 2007): 393–97. http://dx.doi.org/10.1016/s0021-7697(07)73993-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Boutayeb, S., Y. Bensouda, Z. Fadoulkhair, K. Bakkraoui, M. Bachouchi, and H. Errihani. "Les thérapies ciblées dans la cancérologie digestive." Pathologie Biologie 60, no. 4 (August 2012): 264–68. http://dx.doi.org/10.1016/j.patbio.2012.05.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lecomte, T., and E. Vaillant. "Actualités en cancérologie digestive à l’UEGW 2016." Acta Endoscopica 47, no. 1 (January 19, 2017): 36–38. http://dx.doi.org/10.1007/s10190-017-0582-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Montravers, F., and J. N. Talbot. "Tomographie par émission de positons en cancérologie digestive." EMC - Radiologie et imagerie médicale - Abdominale - Digestive 7, no. 2 (June 2012): 1–14. http://dx.doi.org/10.1016/s1879-8527(12)55045-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Azaloux, H., M. A. Chanol, P. Escarmant, S. Gromb, P. Cart-Lami, and A. Moris. "Cancérologie digestive en Martinique et marqueurs tumoraux plasmatiques." Trait - d'Union 2, no. 2 (June 1987): 42–44. http://dx.doi.org/10.1016/s0980-9090(87)80029-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Bazine, A., M. Fetohi, E. Choukri, K. A. Slimani, M. Ichou, and H. Errihani. "Toxicité cutanée des thérapies ciblées en cancérologie digestive." Journal Africain d'Hépato-Gastroentérologie 8, no. 4 (August 22, 2014): 212–16. http://dx.doi.org/10.1007/s12157-014-0562-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Rougier, P., P. Pienkovski, and P. Michel. "Les hépatogastroentérologues et la chimiothérapie en cancérologie digestive." Côlon & Rectum 4, no. 4 (November 2010): 241–42. http://dx.doi.org/10.1007/s11725-010-0257-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Bretagne, Jean-François, and Sylvain Manfredi. "Quel est le rôle de l’hépato-gastroentérologue en cancérologie digestive ?" Gastroentérologie Clinique et Biologique 30, no. 11 (November 2006): 1241–43. http://dx.doi.org/10.1016/s0399-8320(06)73531-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Coulom, Pierre, and Patrice Pienkowski. "Premier Symposium Cregg De Cancérologie Digestive Libérale Aux JFPD 2008." Acta Endoscopica 38, no. 2 (June 2008): 193. http://dx.doi.org/10.1007/bf02961958.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Legoux, Jean-Louis, Laurent Bedenne, Jean-François Seitz, Denis Pezet, Philippe Rougier, Olivier Bouché, Jean-Claude Barbare, et al. "Quels changements dans le Thésaurus National de Cancérologie Digestive en 2005 ?" Gastroentérologie Clinique et Biologique 30, no. 10 (October 2006): 1191–95. http://dx.doi.org/10.1016/s0399-8320(06)73510-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Montravers, Franc¸oise, Eric Zerbib, Dany Grahek, Khaldoun Kerrou, Nassima Younsi, and Jean-Noël Talbot. "Tomographie par émission de positons au [18F]-fluorodésoxyglucose en cancérologie digestive." EMC - Radiologie et imagerie médicale - Abdominale - Digestive 1, no. 1 (January 2006): 1–10. http://dx.doi.org/10.1016/s1879-8527(06)74699-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Alves, Arnaud, and Olivier Dejardin. "Comment étudier l’influence des inégalités sociales de santé en cancérologie digestive ?" Hépato-Gastro & Oncologie Digestive 30, no. 7 (September 2023): 657–60. http://dx.doi.org/10.1684/hpg.2023.2619.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Bouché, O., E. Scaglia, Z. Reguiai, V. Singha, H. Brixi-Benmansour, and S. Lagarde. "Biothérapies ciblées en cancérologie digestive : prise en charge de leurs effets secondaires." Gastroentérologie Clinique et Biologique 33, no. 4 (April 2009): 306–22. http://dx.doi.org/10.1016/j.gcb.2009.02.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Methy, N., L. Bedenne, and F. Bonnetain. "Critères de substitution: méthodes de validation et état des lieux en cancérologie digestive." Bulletin du Cancer 96, no. 5 (May 2009): 591–95. http://dx.doi.org/10.1684/bdc.2009.0858.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Rialland, F., F. Méchinaud, H. Piloquet, M. F. De La Cochetière, and D. Darmaun. "SFCE-P16 – Cancérologie – Etat nutritionnel et marqueurs d’inflammation digestive après greffe de moelle." Archives de Pédiatrie 15, no. 5 (June 2008): 1011. http://dx.doi.org/10.1016/s0929-693x(08)72358-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Guigou, David. "Les douleurs en cancérologie digestive : regarder au-delà pour réussir à les traiter." Gastroentérologie Clinique et Biologique 28, no. 5 (May 2004): 11–16. http://dx.doi.org/10.1016/s0399-8320(04)94982-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Bouché, Olivier. "Les biothérapies ciblées en cancérologie digestive : une nouvelle ère dans la stratégie thérapeutique ?" Gastroentérologie Clinique et Biologique 29, no. 5 (May 2005): 495–500. http://dx.doi.org/10.1016/s0399-8320(05)82118-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

LLEDO, Gérard, and Pascal ARTRU. "Un nouveau Cancéro digest pour ne rien rater de l’actualité en cancérologie digestive…" Cancéro digest, no. 1 (2009): 1. http://dx.doi.org/10.4267/2042/25060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Culine, S., J. Gligorov, I. Krakowski, P. Marti, J.-P. Metges, D. Serin, M. Schneider, and M. Spielmann. "Une première collaboration entre Oncologie et la Fédération Française de Cancérologie Digestive (FFCD) !" Oncologie 16, no. 11-12 (December 2014): 483. http://dx.doi.org/10.1007/s10269-014-2476-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Rouillon, J. M., and P. Pienkowski. "Quelle place pour les hépato-gastro-entérologues dans l’exercice de la cancérologie digestive?" Acta Endoscopica 38, S1 (March 2008): S30—S33. http://dx.doi.org/10.1007/s101900800029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Campedel, L., S. Assoun, S. Bécourt, O. Nguyen, F. Ledoux, L. Doucet, M. Espié, and L. Teixeira. "Toxicités sévères des immunothérapies du cancer." Médecine Intensive Réanimation 27, no. 6 (November 2018): 522–36. http://dx.doi.org/10.3166/rea-2018-0070.

Full text

Abstract:

L’immunothérapie représente une avancée récente et importante en cancérologie. Les inhibiteurs de checkpoints immunitaires, ciblant les protéines PD-1, PD-L1 et CTLA-4, sont les thérapies les plus prometteuses et sont utilisés dans la prise en charge de plusieurs cancers. Les toxicités associées à ces traitements sont généralement moins fréquentes et moins graves que celles associées aux chimiothérapies et à la plupart des thérapies ciblées. Cependant, il existe un certain nombre de toxicités spécifiques de ce type de traitement, qui peuvent parfois être sévères et dont les plus fréquentes sont les toxicités pulmonaire, digestive, endocrinienne et cutanée. Dans cette mise au point, nous reviendrons sur la fréquence, le mécanisme et les principes de traitement des différentes toxicités sévères associées à l’immunothérapie.

APA, Harvard, Vancouver, ISO, and other styles

29

Metges, J. P., A. Volant, F. Grudé, O. Pradier, C. Riche, E. Gamelin, and L. Corcos. "La recherche clinique en cancérologie digestive: de la cible à la véritable personnalisation du traitement?" Oncologie 11, no. 6 (June 2009): 325–30. http://dx.doi.org/10.1007/s10269-009-1079-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Lledo, G. "Modalités d’exercice de la cancérologie digestive par un hépato-gastro-entérologue (HGE) en secteur libéral." Acta Endoscopica 33, S3 (June 2003): 462–63. http://dx.doi.org/10.1007/bf03002389.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Debrix, I., M. Sitbon, A. Khalil, A. Benomar, A. Becker, and T. André. "Référentiel de bon usage et Thésaurus national de cancérologie digestive : analyse des écarts à l’hôpital Tenon." Bulletin du Cancer 96, no. 2 (February 2009): 147–55. http://dx.doi.org/10.1684/bdc.2008.0820.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Methy, N., F. Bonnetain, and L. Bedenne. "Critères de substitution de la survie globale dans les essais cliniques de cancérologie digestive : quels candidats ?" Revue d'Épidémiologie et de Santé Publique 56, no. 2 (May 2008): 87–88. http://dx.doi.org/10.1016/j.respe.2008.03.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Malka, David, Olivier Chapet, Laurence Chiche, Thierry De Baere, Clarisse Dromain, Frédéric Prat, Jean-Robert Delpero, and Olivier Rosmorduc. "Cancer des voies biliaires : les tables de la loi. Les recommandations du Thésaurus National de Cancérologie Digestive." Cancéro digest 1, no. 2 (2009): 112. http://dx.doi.org/10.4267/2042/28036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Legoux, J. L., P. Michel, P. Pienkowski, R. Faroux, B. Napoléon, T. Ponchon, O. Rosmorduc, et al. "CO.87 Pratique de la cancérologie digestive par les hépato-gastroentérologues (HGE) : enquête nationale de la FSMAD." Gastroentérologie Clinique et Biologique 33, no. 3 (March 2009): A144. http://dx.doi.org/10.1016/s0399-8320(09)72883-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Legoux, J. L., P. Pienkowski, B. Napoléon, G. Lledo, C. Lecaille, F. Ricard, and P. Rougier. "P.235 Pratique de la cancérologie digestive par les hépato-gastroentérologues libéraux : enquête nationale 2008 FSMAD-FFCD." Gastroentérologie Clinique et Biologique 33, no. 3 (March 2009): A166. http://dx.doi.org/10.1016/s0399-8320(09)72926-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Dargent, F. "Particularités de la cancérologie animale Etude rétrospective de 50 cas de pathologie tumorale digestive spontanée du chien." Acta Endoscopica 29, no. 5 (October 1999): 585–91. http://dx.doi.org/10.1007/bf03022173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

May., Mabro. "Congrès annuel de l'American Society of Clinical Oncology, Orlando, Floride, mai 2002. L'actualité en cancérologie mammaire et digestive." La Revue de Médecine Interne 23, no. 12 (December 2002): 957–59. http://dx.doi.org/10.1016/s0248-8663(02)00744-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Lepage, C., A. M. Bouvier, G. Launoy, and J. Faivre. "D1-4 - Évaluation du résultat des thérapeutiques lourdes en cancérologie digestive chez les patients de 80 ans et plus." Revue d'Épidémiologie et de Santé Publique 54 (August 2006): 37. http://dx.doi.org/10.1016/s0398-7620(06)76837-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Legoux, J. L., R. Faroux, P. Rougier, J. Butel, F. Ricard, and H. Hagège. "P.234 Pratique de la cancérologie digestive par les hépato-gastroentérologues des Hôpitaux Généraux : enquête nationale 2008 FSMAD-FFCD." Gastroentérologie Clinique et Biologique 33, no. 3 (March 2009): A165. http://dx.doi.org/10.1016/s0399-8320(09)72925-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Crehange, Gilles, Philippe Maingon, Karine Peignaux, Tan Dat N′guyen, Xavier Mirabel, Christian Marchal, Pierre Verrelle, Bernard Roullet, Franck Bonnetain, and Laurent Bedenne. "Phase III Trial of Protracted Compared With Split-Course Chemoradiation for Esophageal Carcinoma: Fédération Francophone de Cancérologie Digestive 9102." Journal of Clinical Oncology 25, no. 31 (November 1, 2007): 4895–901. http://dx.doi.org/10.1200/jco.2007.12.3471.

Full text

Abstract:

Purpose Chemoradiotherapy (CRT) is an alternative to surgery for resectable locally advanced esophageal carcinoma (RLA-EC). We investigated the heterogeneity of the treatment benefits across subgroups of patients, defined according to the radiation scheme. Patients and Methods Between February 1993 and December 2000, 451 patients were enrolled. The following two schemes were allowed: protracted radiotherapy (P-RT), which scheduled 46 Gy over 4.5 weeks or split-course radiotherapy (SC-RT) with two 1-week courses of 15 Gy. Two courses of cisplatin and fluorouracil were delivered concomitantly. In case of exclusive CRT, a further course of 20 Gy over 2 weeks in the P-RT group and one 1-week course of 15 Gy in the SC-RT group were delivered with three courses of chemotherapy. SC-RT and P-RT were administered to 285 patients (64%) and 161 patients (36%), respectively. Results For P-RT versus SC-RT, the response rate to induction CRT was 67% v 68%, respectively (P = .09), and 2-year local relapse-free survival rate was 76.7% v 56.8%, respectively (P = .002). Shorter tumor length and P-RT were associated with better local control in multivariate analysis (P = .002 for both). After a median follow-up time of 47.4 months, 2-year overall survival rate was 37.1% for P-RT compared with 30.5% for SC-RT (P = .25). Independent prognostic factors on survival were tumor diameter (P = .02), weight loss of 10% or less (P = .05), and response to induction CRT (P = .002). Conclusion Patients with RLA-EC treated with P-RT had better local control than patients treated with SC-RT. Response to induction CRT is a determinant prognostic factor on survival.

APA, Harvard, Vancouver, ISO, and other styles

41

Michel, P., J. L. Legoux, T. Ponchon, O. Rosmorduc, G. Cadiot, F. Ricard, and P. Rougier. "P.233 Pratique de la cancérologie digestive par les hépato-gastroentérologues des Centres Hospitalo-Universitaires : enquête nationale 2008 FSMAD-FFCD." Gastroentérologie Clinique et Biologique 33, no. 3 (March 2009): A165. http://dx.doi.org/10.1016/s0399-8320(09)72924-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Phelip, Jean-Marc, Véronique Vendrely, Florian Rostain, Fabien Subtil, Jean-Louis Jouve, Mohamed Gasmi, Pierre Michel, et al. "Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study." European Journal of Cancer 50, no. 17 (November 2014): 2975–82. http://dx.doi.org/10.1016/j.ejca.2014.08.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Piessen, G. "Quel est le rôle de la chirurgie en cas de réponse clinique complète après chimio(radio)thérapie première en cancérologie digestive ?" Journal de Chirurgie Viscérale 151, no. 6 (December 2014): 435–37. http://dx.doi.org/10.1016/j.jchirv.2014.07.010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Bedenne, L., AL Villing, and B. Chauffert. "Lutte contre le cancer du pancréas exocrine: stagnation ou progrès ? Le point de vue de la Fondation française de cancérologie digestive (FFCD)." Cancer/Radiothérapie 1, no. 5 (November 1997): 555–63. http://dx.doi.org/10.1016/s1278-3218(97)89638-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Michel, Pierre, Gilles Breysacher, Françoise Mornex, Jean François Seitz, Denis Pere-Verge, Isabelle Martel-Lafay, Roger Faroux, et al. "Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308." European Journal of Cancer 50, no. 6 (April 2014): 1076–83. http://dx.doi.org/10.1016/j.ejca.2013.12.009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Renfro, Lindsay A., Richard M. Goldberg, Axel Grothey, Alberto Sobrero, Richard Adams, Matthew T. Seymour, Volker Heinemann, et al. "Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database." Journal of Clinical Oncology 35, no. 17 (June 10, 2017): 1929–37. http://dx.doi.org/10.1200/jco.2016.71.5771.

Full text

Abstract:

Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled. Multivariable logistic regression models for 30-, 60-, and 90-day mortality were constructed, including clinically and statistically significant patient and disease factors and interaction terms. A calculator (nomogram) for 90-day mortality was developed and validated internally using bootstrapping methods and externally using a 10% random holdout sample from each trial. The impact of early progression on the likelihood of survival to 90 days was examined with time-dependent Cox proportional hazards models. Results Mortality rates were 1.4% at 30 days, 3.4% at 60 days, and 5.5% at 90 days. Among baseline factors, advanced age, lower body mass index, poorer performance status, increased number of metastatic sites, BRAF mutant status, and several laboratory parameters were associated with increased likelihood of early mortality. A multivariable model for 90-day mortality showed strong internal discrimination (C-index, 0.77) and good calibration across risk groups as well as accurate predictions in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectal cancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.

APA, Harvard, Vancouver, ISO, and other styles

47

Bedenne, L., J. L. Legoux, T. Aparicio, R. Guimbaud, O. Bouché, F. Ricard, and P. Rougier. "P.232 Pratique de la cancérologie digestive par les hépato-gastroentérologues : évolutions de 2000 à 2008 au travers des enquêtes nationales FSMAD-FFCD." Gastroentérologie Clinique et Biologique 33, no. 3 (March 2009): A164. http://dx.doi.org/10.1016/s0399-8320(09)72923-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Crespel, Céline, Cloé Brami, Paul de Boissieu, Camille Mazza, Kevin Chauvet, Amélie Lemoine, Benoit Gavlak, et al. "Évaluation de la faisabilité d’un programme d’activité physique adaptée en hôpital de jour de cancérologie digestive : à partir du point de vue des patients." Bulletin du Cancer 105, no. 3 (March 2018): 228–33. http://dx.doi.org/10.1016/j.bulcan.2017.11.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Lieu, Christopher H., Lindsay A. Renfro, Aimery de Gramont, Jeffrey P. Meyers, Timothy S. Maughan, Matthew T. Seymour, Leonard Saltz, et al. "Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program." Journal of Clinical Oncology 32, no. 27 (September 20, 2014): 2975–82. http://dx.doi.org/10.1200/jco.2013.54.9329.

Full text

Abstract:

Purpose This study addressed whether age is prognostic for overall survival (OS) or progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC). Patients and Methods A total of 20,023 patients from 24 first-line clinical trials in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were analyzed. Primary age effects and interactions with age, sex, performance status (PS), and metastatic site were modeled using Cox proportional hazards stratified by treatment arm within study. Results Of total patients, 3,051 (15%) were age ≤ 50 years. Age was prognostic for both OS (P < .001) and PFS (P < .001), with U-shaped risk (ie, highest risk was evident in youngest and oldest patients). Relative to patients of middle age, the youngest patients experienced 19% (95% CI, 7% to 33%) increased risk of death and 22% (95% CI, 10% to 35%) increased risk of progression. The oldest patients experienced 42% (95% CI, 31% to 54%) increased risk of death and 15% (95% CI, 7% to 24%) increased risk of progression or death. This relationship was more pronounced in the first year of follow-up. Age remained marginally significant for OS (P = .08) when adjusted for PS, sex, and presence of liver, lung, or peritoneal metastases, and age was significant in an adjusted model for PFS (P = .005). The age effect did not differ by site of metastatic disease, year of enrollment, type of therapy received, or biomarker mutational status. Conclusion Younger and older age are associated with poorer OS and PFS among treated patients with mCRC. Younger and older patients may represent higher-risk populations, and additional studies are warranted.

APA, Harvard, Vancouver, ISO, and other styles

50

Boige, V., J. L. Raoul, J. P. Pignon, O. Bouche, E. Boucher, J. F. Blanc, J. F. Seitz, L. Bedenne, N. Dupouy, and M. Ducreux. "Preliminary results of capecitabine - oxaliplatin (XELOX) in hepatocellular carcinoma (HCC): A phase II trial of the Fédération Francophone de Cancérologie Digestive (FFCD 2003–03 trial)." Journal of Clinical Oncology 23, no. 16_suppl (June 2005): 4128. http://dx.doi.org/10.1200/jco.2005.23.16_suppl.4128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Cancérologie digestive'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles